Cancer Stem Cell News 8.09 March 13, 2019 | |
| |
TOP STORYGboxin Is an Oxidative Phosphorylation Inhibitor that Targets Glioblastoma The authors describe Gboxin, a small molecule that specifically inhibits the growth of primary mouse and human glioblastoma cells but not that of mouse embryonic fibroblasts or neonatal astrocytes. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Investigators report LSECtin, a transmembrane protein highly expressed on tumor-associated macrophages, enhanced stemness of breast cancer cells. [Cell Res] Abstract The authors demonstrated an essential role of NCAM1 in the regulation of cell survival and stress resistance. Perturbation of NCAM1 induced cell death or differentiation and sensitized leukemic blasts towards genotoxic agents in vitro and in vivo. [Blood] Abstract Stem Cell Persistence in CML Is Mediated by Extrinsically Activated JAK1-STAT3 Signaling Researchers showed therapy-resistant cell-extrinsic STAT3 activation in tyrosine kinase inhibitor-sensitive CML cells, using cell lines, HoxB8-immortalized murine BM cells, and primary human stem cells. [Leukemia] Abstract Expression and Functional Relevance of Long Non-Coding RNAs in Acute Myeloid Leukemia Stem Cells DANCR knock-down in leukemia stem cells resulted in decreased stem-cell renewal and quiescence. Scientists showed that targeting Dancr in vivo using a primary murine model of acute myeloid leukemia prolonged the survival of mice after serial transplantation. [Leukemia] Abstract A Cell Type-Selective Apoptosis-Inducing Small Molecule for the Treatment of Brain Cancer Investigators report the identification of a small molecule, termed RIPGBM, from a cell-based chemical screen that selectively induced apoptosis in multiple primary patient-derived glioblastoma multiforme cancer stem cell cultures. [Proc Natl Acad Sci USA] Full Article Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy To identify potential therapeutic options for cancer patients with TP53 mutations, scientists profiled 127 FDA approved chemotherapy drugs against human embryonic stem cells in which they engineered TP53 deletion by genome editing. [Cancer Res] Abstract A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-Like Cells Researchers identified two aldehyde dehydrogenase (ALDH)1A family selective inhibitors (ALDH1Ai). ALDH1Ai preferentially killed CD133+ ovarian cancer stem-like cells. [Cell Rep] Full Article | Graphical Abstract Using nonoverlapping, independent RNA sequencing and gene expression profiling datasets, the authors revealed that TP73-AS1 constituted a clinically relevant lncRNA in glioblastoma multiform (GBM). Specifically, they demonstrated significant overexpression of TP73-AS1 in primary GBM samples, which was particularly increased in GBM cancer stem cells. [Cell Death Dis] Full Article Investigators observed that 4-methylumbelliferone treatments in an animal model down-regulated the mRNA expressions of hyaluronic acid-related genes Has3 and Hyal2 only in HBV-TG but not in normal WT. [Sci Rep] Full Article Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News. | |
| |
REVIEWSTherapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies The authors review some of the ongoing cancer stem cell therapeutic targeting strategies in gastrointestinal malignancies. [Biomedicines] Abstract Visit our reviews page to see a complete list of reviews in the cancer stem cell research field. | |
| |
INDUSTRY NEWSSTEMCELL Technologies Wins Deloitte Best Managed Companies Award STEMCELL Technologies announced that the company has been selected as a winner of Canada’s Best Managed Companies program for 2019. Canada’s Best Managed Companies is the country’s leading business awards program, recognizing excellence in the management abilities and practices of Canadian owned and managed companies with revenues over $15 million. [STEMCELL Technologies Inc.] Press Release AbbVie announced that the FDA granted a fifth Breakthrough Therapy Designation to venetoclax, for use in combination with obinutuzumab as a fixed duration investigational combination, for untreated adult patients with chronic lymphocytic leukemia. [AbbVie Inc.] Press Release | |
| |
POLICY NEWSIn a First, US Private Sector Employs Nearly as Many PhDs as Schools Do The job market for US science and engineering PhDs is about to pass a long-anticipated milestone. For decades, educational institutions have been the largest employer of PhDs. In 1997, for instance, they eclipsed private sector employment by 11 percentage points, according to the US National Science Foundation’s biennial Survey of Doctorate Recipients. [ScienceInsider] Editorial Ned Sharpless, Director of the National Cancer Institute, to Be Named Acting FDA Commissioner The Trump administration announced it would name Ned Sharpless, the director of the National Cancer Institute, the acting commissioner of the FDA next month. The announcement came just a week after the current commissioner, Scott Gottlieb, announced he plans to resign in early April. [STAT News] Editorial
| |
EVENTSNEW 8th InterAmerican Oncology Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Malignant Hematopoiesis (Karolinska Institutet) NEW Lecturer – Developmental Biology and Cancer (University College London) Postdoctoral Positions – Stem Cell and Cancer Biology (Columbia University Irving Medical Center) Postdoctoral Position – Ovarian Cancer Stem Cells (University of Minnesota) Postdoctoral Position – Stem Cell Aging and Cancer (University of California – San Francisco) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|